Hologic announced the completion of its acquisition of Gynesonics, Inc., a transaction valued at $350 million. This strategic acquisition enhances Hologic's GYN Surgical portfolio with a novel, minimally invasive option for uterine fibroid removal.
The Gynesonics acquisition complements Hologic's existing MyoSure platform, which treats smaller fibroids, and its Acessa platform for larger, laparoscopic cases. This expanded offering allows Hologic to address a broader range of fibroid sizes and locations.
This move is expected to strengthen Hologic's market position in minimally invasive gynecological solutions, providing more comprehensive treatment options for women and driving growth in the surgical segment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.